Kura Oncology, Inc. $KURA Stock Holdings Increased by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC lifted its position in Kura Oncology, Inc. (NASDAQ:KURA) by 285.6% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 158,850 shares of the company’s stock after acquiring an additional 117,650 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Kura Oncology were worth $1,291,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. SG Americas Securities LLC grew its position in shares of Kura Oncology by 214.1% during the 4th quarter. SG Americas Securities LLC now owns 151,715 shares of the company’s stock valued at $1,576,000 after buying an additional 103,411 shares during the last quarter. UBS Group AG lifted its holdings in shares of Kura Oncology by 118.3% in the 4th quarter. UBS Group AG now owns 1,060,025 shares of the company’s stock worth $11,014,000 after purchasing an additional 574,455 shares during the last quarter. Nan Fung Trinity HK Ltd. boosted its position in Kura Oncology by 317.9% during the 4th quarter. Nan Fung Trinity HK Ltd. now owns 964,880 shares of the company’s stock valued at $10,025,000 after purchasing an additional 734,000 shares during the period. Moody Aldrich Partners LLC acquired a new stake in Kura Oncology in the fourth quarter worth $1,867,000. Finally, OP Asset Management Ltd bought a new stake in Kura Oncology in the first quarter valued at $2,202,000.

Insider Activity at Kura Oncology

In other Kura Oncology news, insider Mollie Leoni sold 84,929 shares of the firm’s stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $9.82, for a total value of $834,002.78. Following the completion of the transaction, the insider directly owned 182,345 shares in the company, valued at $1,790,627.90. This trade represents a 31.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 7.60% of the stock is currently owned by insiders.

Kura Oncology Price Performance

Shares of NASDAQ:KURA traded down $0.63 on Friday, reaching $11.45. 1,338,778 shares of the company traded hands, compared to its average volume of 1,662,442. Kura Oncology, Inc. has a fifty-two week low of $5.45 and a fifty-two week high of $12.49. The company’s 50 day moving average is $9.99 and its 200-day moving average is $9.27. The stock has a market capitalization of $1.02 billion, a PE ratio of -3.42 and a beta of 0.35. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.15 and a quick ratio of 6.14.

Kura Oncology (NASDAQ:KURA) last issued its earnings results on Tuesday, May 12th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.05. Kura Oncology had a negative return on equity of 141.95% and a negative net margin of 411.19%.The business had revenue of $18.27 million for the quarter, compared to analysts’ expectations of $25.97 million. As a group, analysts anticipate that Kura Oncology, Inc. will post -3.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

KURA has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Kura Oncology in a research report on Tuesday, April 21st. Mizuho decreased their price objective on Kura Oncology from $30.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday, March 24th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research report on Thursday, June 4th. Wall Street Zen upgraded shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, Citigroup restated a “market outperform” rating on shares of Kura Oncology in a research report on Thursday, May 28th. Ten investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Kura Oncology has an average rating of “Moderate Buy” and a consensus target price of $25.46.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.